Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the treatment of adult patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
This is written in the approval document as:
As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | BRCA1 oncogenic variants | Prostate Adenocarcinoma | Olaparib | |
| HSE (1) | BRCA1 pathogenic variants | Prostate Adenocarcinoma | Olaparib | |
| HSE (1) | BRCA2 oncogenic variants | Prostate Adenocarcinoma | Olaparib | |
| HSE (1) | BRCA2 pathogenic variants | Prostate Adenocarcinoma | Olaparib |